Sunshine Biopharma Announces Publication Of Significant Coronavirus Research Results In The Journal Of Medicinal Chemistry
Sunshine Biopharma Announces Publication Of Significant Coronavirus Research Results In The Journal Of Medicinal Chemistry
Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18%
美國目前新冠病毒感染的測試陽性率爲18%
Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacy
開發一種新型抗病毒化合物XR8-23（Compound 10），目標是針對SARS-CoV-2編碼融合樣蛋白酶（PLpro），同時具有亞微米級的力量和動物模型的功效
XR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic properties
XR8-23（Compound 10）在小鼠肺部顯示出顯著藥物積累和有利的藥代動力學特性
Research was conducted in collaboration with the University of Arizona
該研究是與亞利桑那大學合作進行的
FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS-CoV-2 infection.
2024年9月4日，來自FORt LAUDERDALE, FL / ACCESSWIRE /世紀陽光生物製品公司（NASDAQ:SBFM）（「公司」），一家提供和研究包括腫瘤學和抗病毒學在內的多種治療領域救生藥物的藥品公司，宣佈在《藥物化學雜誌》上發表了新的研究結果。發佈的數據證明了一種具有亞微米級效力和體內效果的融合樣蛋白酶（PLpro）抑制劑在小鼠SARS-CoV-2感染模型中。這項經過同行評議的研究標誌着世紀陽光生物製品在努力開發SARS-CoV-2感染有效治療方面的重要里程碑。
